Mesoblast (ASX:MSB) said it earned gross revenue of $35.1 million from the sale of its mesenchymal stromal cell product Ryoncil for the quarter ending Dec. 31, 2025, up 60% from the quarter ending Sept. 30, 2025, according to a Friday filing with the Australian bourse.
Ryoncil, the company's US Food and Drug Administration-approved product for the treatment of steroid-refractory acute graft-versus-host disease in children under 12 years of age, was available for purchase in the US from March 2025, an earlier filing showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments